Rapid diagnosis of preeclampsia at the point-of-care

MOMM Diagnostics conceives a new generation of in-vitro diagnostic tests for early diagnosis of preeclampsia. Preeclampsia remains to this day one of the leading causes for maternal mortality. Early diagnosis is therefore vital to minimize complications and prepare adequately for birth. The startup is developing a solution using microscale solid-state sensors for electrical detection of biomarkers in blood, which would allow the detection of multiple biomarkers, using a single-use cartridge and a hand-held reader for diagnosis of the condition directly where the patients are being taken care of. Technology originating from results of the FETOPEN project RECORD-IT (Project ID: 664786) has shown promising innovation potential. MOMM Diagnostics aims to verify this potential for commercialization by assessing its competitiveness for point of care applications. The technology promises an increased signal to noise ratio at a smaller form factor and lower cost compared to commercially available technologies. The FET Innovation Launchpad will help to consolidate the intellectual property rights and develop a demonstrator to approach investors.